Literature DB >> 2564204

Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

B Szende1, A Zalatnai, A V Schally.   

Abstract

Female Syrian golden hamsters with N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic cancers were treated with long-acting microcapsular preparations of the 6-D-tryptophan analog of luteinizing hormone-releasing hormone [( D-Trp6]LH-RH), releasing 25 micrograms/day; the somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160), liberating 15 micrograms/day; and the combination of these two peptides. Therapy with analogs was initiated 24 weeks after initial administration of BOP. These treatments resulted in significantly better survival of all animals as compared to BOP controls; body weights of surviving peptide-treated animals were significantly higher than those of the BOP controls. All 15 BOP-control animals had pancreatic cancers. In the group treated with RC-160 four hamsters were free of tumors, whereas therapy with [D-Trp6]LH-RH resulted in seven tumor-free animals, and combination of RC-160 and [D-Trp6]LH-RH resulted in eight tumor-free animals from groups of 15. Only preblastomatous lesions were found in these animals. Average tumor weight of animals in all peptide-treated groups, sacrificed 60 days after beginning the peptide treatment, was significantly lower than that of BOP controls. No significant differences were seen between the various peptide-treated groups. Histologically, analog-treated tumors of hamsters showed striking regressive changes characteristic of programmed cell death (apoptosis). This apoptosis presumably resulted from hormonal effects on tumor cells from prolonged treatment with these analogs of hypothalamic hormones. Our present data confirm the beneficial effect of long-acting microcapsules of [D-Trp6]LH-RH and RC-160 on pancreatic carcinoma and suggest a mode of action for these peptides. The feasibility of applying this treatment with analogs of hypothalamic hormones to human pancreatic carcinoma can be envisioned from these studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564204      PMCID: PMC286755          DOI: 10.1073/pnas.86.5.1643

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  What is apoptosis?

Authors:  A H Wyllie
Journal:  Histopathology       Date:  1986-09       Impact factor: 5.087

2.  Carcinoma of the exocrine pancreas: a sex hormone responsive tumour?

Authors:  B A Greenway
Journal:  Br J Surg       Date:  1987-06       Impact factor: 6.939

3.  Hormonal control of pancreatic cancer growth.

Authors:  C Liebow; M Hierowski; K duSapin
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

4.  Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas.

Authors:  D Gonzalez-Barcena; N E Rangel-Garcia; P L Perez-Sanchez; C Gutierrez-Damperio; F Garcia-Carrasco; A M Comaru-Schally; A V Schally
Journal:  Lancet       Date:  1986-07-19       Impact factor: 79.321

5.  Tamoxifen therapy in unresectable adenocarcinoma of the pancreas.

Authors:  A Wong; A Chan; K Arthur
Journal:  Cancer Treat Rep       Date:  1987 Jul-Aug

6.  Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.

Authors:  R Z Cai; B Szoke; R Lu; D Fu; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.

Authors:  J I Paz-Bouza; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

8.  Pancreatic carcinogenesis: effect of secretin in the hamster- nitrosamine model.

Authors:  A G Howatson; D C Carter
Journal:  J Natl Cancer Inst       Date:  1987-01       Impact factor: 13.506

9.  Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line.

Authors:  M T Hierowski; C Liebow; K du Sapin; A V Schally
Journal:  FEBS Lett       Date:  1985-01-07       Impact factor: 4.124

10.  Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.

Authors:  C Benz; C Hollander; B Miller
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

View more
  23 in total

Review 1.  Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview.

Authors:  A H Wyllie
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Gene expression of gonadotropin-releasing hormone and its receptor in rat pancreatic cancer cell lines.

Authors:  L Wang; L P Xie; R Q Zhang
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 3.  Neurogenesis and neuronal regeneration in the adult fish brain.

Authors:  G K H Zupanc
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2006-02-07       Impact factor: 1.836

Review 4.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

5.  Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.

Authors:  B Szende; K Lapis; T W Redding; G Srkalovic; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

Review 6.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

7.  A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.

Authors:  G Kéri; J Erchegyi; A Horváth; I Mezõ; M Idei; T Vántus; A Balogh; Z Vadász; G Bökönyi; J Seprõdi; I Teplán; O Csuka; M Tejeda; D Gaál; Z Szegedi; B Szende; C Roze; H Kalthoff; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 8.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

9.  Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

Authors:  R R Perry; Y Kang; B Greaves
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

10.  Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.

Authors:  K H Baumann; L Kiesel; M Kaufmann; G Bastert; B Runnebaum
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.